CRIS Current Research Information System

SARTOR, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.393
EU - Europa 3.075
AS - Asia 1.958
AF - Africa 241
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 7
Totale 8.694
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.366
GB - Regno Unito 711
IT - Italia 686
CN - Cina 618
VN - Vietnam 568
SG - Singapore 472
SE - Svezia 445
DE - Germania 365
NL - Olanda 170
IN - India 149
RU - Federazione Russa 148
IE - Irlanda 127
FR - Francia 92
TG - Togo 82
ZA - Sudafrica 57
EE - Estonia 54
FI - Finlandia 52
CI - Costa d'Avorio 50
NG - Nigeria 47
BG - Bulgaria 43
JO - Giordania 38
CH - Svizzera 33
UA - Ucraina 33
BE - Belgio 27
HK - Hong Kong 24
AT - Austria 22
CA - Canada 22
ID - Indonesia 17
IR - Iran 17
JP - Giappone 13
GR - Grecia 10
PL - Polonia 10
LT - Lituania 9
TR - Turchia 9
ES - Italia 8
UZ - Uzbekistan 7
EU - Europa 6
AU - Australia 5
BR - Brasile 4
HR - Croazia 4
KR - Corea 4
LB - Libano 4
MK - Macedonia 4
RS - Serbia 4
BD - Bangladesh 3
CL - Cile 3
CZ - Repubblica Ceca 3
MX - Messico 3
PE - Perù 3
PT - Portogallo 3
BY - Bielorussia 2
HU - Ungheria 2
KG - Kirghizistan 2
LI - Liechtenstein 2
MA - Marocco 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
CO - Colombia 1
EG - Egitto 1
GE - Georgia 1
IL - Israele 1
JM - Giamaica 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
PH - Filippine 1
SA - Arabia Saudita 1
SC - Seychelles 1
TM - Turkmenistan 1
TW - Taiwan 1
UG - Uganda 1
VE - Venezuela 1
Totale 8.694
Salva come PNG Salva come JPEG
Città #
Southend 663
Chandler 429
Dong Ket 418
Singapore 399
Fairfield 271
Ashburn 246
Ann Arbor 180
Houston 158
Santa Clara 146
Wilmington 145
Woodbridge 145
Princeton 134
Bologna 133
Dublin 127
Seattle 120
Boardman 115
Cambridge 98
Beijing 94
Lomé 82
Milan 61
New York 56
Westminster 55
Nanjing 52
Padova 52
Abidjan 50
Abeokuta 47
Helsinki 47
Medford 44
Sofia 43
Amman 38
Berlin 37
Bremen 36
Redmond 29
Florence 28
Brussels 27
Saint Petersburg 27
Bern 26
Redwood City 26
San Diego 25
Turin 25
Jinan 24
Rome 24
Hong Kong 22
Shenyang 22
Hebei 20
Changsha 19
Falkenstein 18
Frankfurt am Main 18
Shanghai 18
Zhengzhou 18
Jakarta 17
Jiaxing 17
Nanchang 17
Tianjin 17
Toronto 16
Los Angeles 15
Guangzhou 13
Vienna 13
Mountain View 12
Nuremberg 12
Falls Church 11
Casalecchio di Reno 10
London 10
Norwalk 10
Fuzhou 9
Wuhan 9
Cesena 8
Forlì 8
Yubileyny 8
Bari 7
Dehradun 7
Des Moines 7
Haikou 7
Hangzhou 7
Hyderabad 7
Paris 7
Phoenix 7
Amsterdam 6
Boydton 6
Dearborn 6
Leawood 6
Madrid 6
Reggio Emilia 6
Taizhou 6
Tokyo 6
Andover 5
Augusta 5
Chengdu 5
Faenza 5
Henderson 5
Irvine 5
Kolkata 5
Kraków 5
Monmouth Junction 5
Moscow 5
Ningbo 5
Olalla 5
Taiyuan 5
Xi'an 5
Athens 4
Totale 5.547
Salva come PNG Salva come JPEG
Nome #
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 241
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 204
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 195
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 193
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 192
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 185
A case report of acute myeloid leukemia and neurofibromatosis 1 180
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 180
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 178
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 160
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 160
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 158
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 154
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 149
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 141
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 137
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 133
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 133
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 133
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 133
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 131
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 131
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 130
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 129
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 129
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 127
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 126
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 126
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 121
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 120
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 117
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 117
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 116
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 115
SNP array reveals a new deletion of JAK2 in AML patients 115
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 115
HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408 110
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 104
Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study 103
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 102
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 102
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 102
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 100
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 99
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 97
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 96
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 96
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 93
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 93
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 92
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 91
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 91
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 89
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 89
Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience 87
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 86
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 85
Nelarabine front-line therapy for adult T-lymphoblastic leukemia/lymphoma (T-LBL/ALL): preliminary results of a single center experience. 82
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 81
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 78
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 77
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 76
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 74
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 70
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 68
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 66
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 66
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 65
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 65
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 58
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement 55
null 52
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 50
null 50
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 42
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 41
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis 39
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 39
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis 38
Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment 37
Posterior reversible encephalopathy syndrome in a B-cell acute lymphoblastic leukemia young adult patient treated with a pediatric-like chemotherapeutic schedule 36
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia 32
Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR 31
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease 31
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 29
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study 28
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents 24
Acute myeloid leukemia mutations: Therapeutic implications 20
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 18
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin 16
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 11
Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment 11
Posterior Reversible Encephalopathy Syndrome in a B-Cell Acute Lymphoblastic Leukemia Young Adult Patient Treated with a Pediatric-like Chemotherapeutic Schedule 9
INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia 6
Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia 2
Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 1
Totale 8.985
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.484
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.484
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020258 0 0 0 0 0 0 0 0 0 114 96 48
2020/20211.144 138 40 19 19 23 41 27 60 103 30 66 578
2021/20221.506 140 35 69 141 137 65 33 117 69 125 322 253
2022/20231.841 184 254 74 235 197 154 49 115 310 45 137 87
2023/2024602 16 73 38 62 38 118 43 62 31 39 53 29
2024/20251.943 113 361 212 207 245 122 268 113 48 254 0 0
Totale 8.985